Search results for " CELL CARCINOMA"
showing 10 items of 477 documents
A review of terms used to define cutaneous squamous cell carcinoma with a poor prognosis.
2020
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in humans and its incidence is both underestimated and on the rise. cSCC is referred to in the literature as high-risk cSCC, locally advanced cSCC, metastatic cSCC, advanced cSCC, and aggressive cSCC. These terms can give rise to confusion and are not always well defined. In this review, we aim to clarify the concepts underlying these terms with a view to standardizing the description of this tumor, something we believe is necessary in light of the new drugs that have been approved or are in development for cSCC.
Factors accelerating recurrences and secondary tumors in cutaneous squamous cell carcinoma
2020
To investigate factors that affect and also decrease the duration for recurrences and secondary tumors in cSCC. A retrospective study was conducted for all patients who were treated for a cSCC of the head and neck between 2009 and 2016. Anamnestic as well as epidemiological and histological data were noted and correlated with the occurrence of recurrences and secondary cancers. The duration between surgery and these events was used to determine if histological factors accelerate their occurrence. The highest risk for recurrences was seen in patients with previous skin cancers (RR 3.23). Histological ulceration (p = 0.003) and grading (p = 0.031) of the tumor were found as significant factor…
Vulvar cancer: a review for dermatologists.
2015
Vulvar malignancies are important tumors of the female reproductive system. They represent a serious health issue with an incidence between 2 and 7 per 100,000 and year. We provide a review about most important cancer entities, i.e., melanoma, squamous cell carcinoma, basal cell carcinoma, neuroendocrine cancer, and skin adnexal malignancies. Squamous cell carcinoma is the most common vulvar malignancy that can develop from vulvar intraepithelial neoplasia or de novo. Basal cell carcinoma represents only 2 % of all vulvar cancers. Melanoma of the vulva exists in two major types—superficial spreading and acral lentiginous. A special feature is the occurrence of multiple vulvar melanomas. Of …
Development of a Prognostic Model for Tongue Squamous Cell Carcinoma
2019
One of the objectives of current researches is to be able to customize the treatment of cancer patients. This can be possible only by better stratifying patients based on the most significant prognostic factors [1]. [...]
38: Drinking Water Source and Cigarette Smoking in Transitional Cell Carcinoma of the Bladder
2006
Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study
2021
Abstract Background Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods Patients’ sample collection was a joint collaboration of the nationwide PANZAR consortium – a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results Of 374 pRCC specimens, 204 type 1 and 97 type 2 we…
2019
Basal cell carcinoma has a potential for early and late metastasis. Depending on the location of the primary site, the relevant lymphatic drainage routes have to be monitored. Regional lymph edema may be a first indicator for metastasizing disease.
MP-02.13 Oncological Long-Term Outcome of Patients Presenting With Chromophobe in Comparison to Non-chromophobe Renal Cell Carcinoma
2011
Bisphosphonates in the era of antiangiogenic targeted therapy
2014
Bone is the second most common metastatic site in patients presenting with metastatic renal cell carcinoma. Bisphosphonates have been approved to reduce bone pain and the risk of skeletal-related events (SREs) in such patients; however, new research suggests bisphosphonates do not improve survival or prevent development of SREs.